Expert Interview
A look at Verona's ensifentrine in the ENHANCE trial and its potential in COPD
Ticker(s): VRNAInstitution: University of Manchester
- Pulmonologist in the Division of Infection, Immunity & Respiratory Medicine University of Manchester with a focus on clinical pharmacology and respiratory medicine
- Treats >400 patients with COPD.
- Principal investigator in over 300 clinical trials and a member of the Global Initiative for the management of COPD Science Committee.
- Currently an editor of the European Respiratory Journal and has over 250 publications.
Roughly how many patients with COPD do you currently manage?
Added By: c_adminOn a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for ensifentrine?
Added By: c_adminWhat're major risks to demonstrating an improvement on SGRQ? What would you consider a clinically meaningful improvement?
Added By: user1a5m4kHow does the inclusion of ~60% of patients with background therapy (versus originally 50% target) impact your perspective on overall probability of success and the baseline traits of the patients that were enrolled?
Added By: user1a5m4kAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
